35228 Federal Register / Vol. 61, No. 130 / Friday, July 5, 1996 / Notices

as studies of directly observed therapy

in various settings and in-patient

compared to out-patient management of

tuberculosis; (2) develops

methodologies for evaluation of

tuberculosis treatment and prevention

program activities and develops

strategies and tools for program selfevaluation; (3) conducts studies of

health-care provider tuberculosis

control practices and assesses the extent

to which recommended practices are

implemented; (4) conducts studies to

assess the cost-effectiveness and public

health impact of recommended

practices; (5) conducts studies to

evaluate and compare strategies to

improve the operation of tuberculosis

treatment and prevention programs; (6)

develops strategies and tools for TB

programs to assess the cost-effectiveness

of various TB prevention and control

interventions; (7) conducts research on

individual and social factors affecting

health-care seeking and treatment

outcomes related to tuberculosis; (8) in

collaboration with the Communications

and Education Branch, conducts

formative research on approaches to

patient and provider education and

public communications; (9) provides

consultation to national and

international organizations on

behavioral and operational research

needs and study designs; (10)

coordinates the writing of studies for

publication of manuscripts in scientific

journals, MMWR, etc; (10) presents

findings at national and scientific

meetings.

Therapeutic and Diagnostics Section

(CK453). (1) Conducts studies of new

drug regimens used in the prevention

and treatment of tuberculosis, including

dosage, duration, and toxicity; (2)

conducts studies of new drugs, drug

delivery systems, immunologic agents

and other treatments for tuberculosis

and latent infection with

Mycobacterium tuberculosis; (3) in

collaboration with others, conducts

studies of new diagnostic tests in

clinical and field trials of more specific

and rapid tests to diagnose tuberculosis

and latent infection with M.

tuberculosis; (4) conducts studies to

evaluate the safety and efficacy of

recommended regimens for the

treatment and prevention of

tuberculosis; (5) provides consultation

and assistance to national and

international organizations on the

design and conduct of clinical trials and

research needs; (6) coordinates the

writing of studies for publication of

manuscripts in scientific journals,

MMWR, etc; (7) presents findings at

national clinical and scientific meetings;

(8) provides support and oversight for

the distribution of investigational drugs

for the treatment and prevention of

tuberculosis by NCID.

Surveillance and Epidemiology

Branch (CK46). (1) Directs national

surveillance of tuberculosis morbidity

and mortality; (2) based on the analysis

of surveillance data, recommends

strategies for national tuberculosis

elimination activities; (3) conducts

studies of special epidemiologic

significance; (4) responds to public and

private inquiries about outbreaks; (5)

assesses the prevalence and trends of

mycobacterial infections in the United

States; (6) develops more precise

epidemiologic methods to identify

persons with mycobacterial infections;

(7) assesses the risk, in collaboration

with NCID and the National Institute for

Occupational Safety and Health, of

mycobacterial infections and diseases

among different segments of the

population, such as health care workers,

correctional facility employees and

inmates, and homeless persons; (8)

provides consultation to other federal

agencies, state and local health

departments, and national

organizations.

Epidemiology Section (CK462). (1)

Conducts and coordinates investigations

of major outbreaks of tuberculosis,

including multidrug-resistant

tuberculosis; (2) analyzes investigation

findings and relates the results and

recommendations of the investigations

to the involved outside agencies and

State health departments; (3) conducts

studies to assess the characteristics of

persons with M. tuberculosis and HIV

co-infection in order to develop and

implement intervention strategies, in

collaboration with others; (4) conducts

case control, cohort, and other studies of

the epidemiology of TB disease and

infection; (5) conducts studies of

restriction fragment length

polymorphism (RFLP) techniques in the

epidemiology of tuberculosis, in

collaboration with others; (6) assess the

prevalence of, and risk factors for,

infection with M. tuberculosis in the

United States through surveys and

special studies; (7) conducts studies of

the epidemiology of drug resistance in

the United States, in collaboration with

others; (8) prepares manuscripts for

publication in scientific journals, and

the MMWR; (9) presents findings at

scientific meetings; (10) responds to

public and private inquiries about the

epidemiology of tuberculosis.

Surveillance Section (CK463). (1)

Conducts national surveillance for

tuberculosis morbidity through the

expanded surveillance system; (2)

implements and provides technical

support for the computer software used

by the state and local health

departments to transmit data from the

reporting areas to CDC; (3) analyzes data

from the surveillance system to

determine risk factors for the increases

and/or decreases in tuberculosis

morbidity and disseminates results

through scientific journals, periodic

reports and public presentations; (4)

monitors the impact of immigration to

the trends and projections of TB

morbidity in the United States; (8)

responds to public and private inquiries

about surveillance findings.

Delete in its entirety the title and

functional statement for the National

Center for Prevention Services (CM).

Dated: June 20, 1996.

David Satcher,

Director, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 96–16855 Filed 7–3–96; 8:45 am]

BILLING CODE 4160–18–M

Food and Drug Administration

[Docket No. 94F–0393]

Asahi Denka Kogyo K. K.; Withdrawal

of Food Additive Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

withdrawal, without prejudice to a

future filing, of a food additive petition

(FAP 4B4434), filed by Asahi Denka

Kogyo K. K., proposing that the food

additive regulations be amended to

provide the expanded safe use of

phosphorous acid, cyclic

neopentanetetrayl bis(2,6-di-tert-butyl4-methylphenyl)ester as an antioxidant

and/or stabilizer at a level not to exceed

0.25 percent by weight in olefin

copolymers in contact with certain food

categories, and at levels not to exceed

0.10 percent by weight in either olefin

copolymers or polypropylene in contact

with certain other food categories.

FOR FURTHER INFORMATION CONTACT: Vir

D. Anand, Center for Food Safety and

Applied Nutrition (HFS–216), Food and

Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: In a notice

published in the Federal Register of

November 23, 1994 (59 FR 60363), FDA

announced that a food additive petition

(FAP 4B4434) had been filed by Asahi

Denka Kogyo K. K., 2, Sirahata 5-

Chome, Urawa City, Saitama 366, Japan.

The petition proposed to amend the

food additive regulations in § 178.2010
Federal Register / Vol. 61, No. 130 / Friday, July 5, 1996 / Notices 35229

Antioxidants and/or stabilizers for

polymers (21 CFR 178.2010) to provide

for the expanded safe use of

phosphorous acid, cyclic

neopentanetetrayl bis(2,6-di-tert-butyl4-methylphenyl)ester for use (i) at levels

not to exceed 0.25 percent by weight of

olefin polymers complying with

§ 177.1520 (21 CFR 177.1520) in contact

with foods of types I, II, III, IV–B, VI–

B, and VIII, as described in Table 1, and

under conditions of use B through H

described in Table 2 of § 176.170(c) (21

CFR 176.170(c)) of this chapter, and

with foods of types IV–A, V, VI–A, VI–

C, VII–A, and IX, under conditions of

use C through G, as described in

§ 176.170(c) of this chapter, Tables 1

and 2 respectively; and (ii) at levels not

to exceed 0.10 percent by weight of

either olefin polymers or polypropylene

complying with § 177.1520 which may

be used only in contact with foods of

types IV–A, V, VI–C, VII–A, and IX,

under conditions of use H, as described

in § 176.170(c) of this chapter, Tables 1

and 2 respectively. Asahi Denka Kogyo

K. K. has now withdrawn the petition

without prejudice to a future filing (21

CFR 171.7).

Dated: June 12, 1996.

Alan M. Rulis,

Director, Office of Premarket Approval,

Center for Food Safety and Applied Nutrition.

[FR Doc. 96–17104 Filed 7–3–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96F–0214]

Ciba-Geigy Corp.; Filing of Food

Additive Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Ciba-Geigy Corp. has filed a

petition proposing that the food additive

regulations be amended to provide for

the safe use of 2,9-dichloro-5,12-

dihydroquinone[2,3-b]acridine-7,14-

dione (C. I. Pigment Red 202) as a

colorant in polymers used in contact

with food.

DATES: Written comments on

petitioner’s environmental assessment

by August 5, 1996.

ADDRESSES: Submit written comments

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, 12420 Parklawn Dr.,

rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Vir

D. Anand, Center for Food Safety and

Applied Nutrition (HFS–216), Food and

Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: Under the

Federal Food, Drug, and Cosmetic Act

(sec. 409(b)(5) (21 U.S.C. 348(b)(5))),

notice is given that a food additive

petition (FAP 6B4512) has been filed by

Ciba-Geigy Corp., 335 Water St.,

Newport, DE 19804. The petition

proposes to amend the food additive

regulations in § 178.3297 Colorants for

polymers (21 CFR 178.3297) to provide

for the safe use of 2,9-dichloro-5,12-

dihydroquinone[2,3-b]acridine-7,14-

dione (C. I. Pigment Red 202) as a

colorant in polymers used in contact

with food.

The potential environmental impact

of this action is being reviewed. To

encourage public participation

consistent with regulations promulgated

under the National Environmental

Policy Act (40 CFR 1501.4(b)), the

agency is placing the environmental

assessment submitted with the petition

that is the subject of this notice on

display at the Dockets Management

Branch (address above) for public

review and comment. Interested persons

may, on or before (insert date 30 days

after date of publication in the Federal

Register), submit to the Dockets

Management Branch (address above)

written comments. Two copies of any

comments are to be submitted, except

that individuals may submit one copy.

Comments are to be identified with the

docket number found in brackets in the

heading of this document. Received

comments may be seen in the office

above between 9 a.m. and 4 p.m.,

Monday through Friday. FDA will also

place on public display any

amendments to, or comments on, the

petitioner’s environmental assessment

without further announcement in the

Federal Register. If, based on its review,

the agency finds that an environmental

impact statement is not required and

this petition results in a regulation, the

notice of availability of the agency’s

finding of no significant impact and the

evidence supporting that finding will be

published with the regulation in the

Federal Register in accordance with 21

CFR 25.40(c).

Dated: June 20, 1996.

George H. Pauli,

Acting Director, Office of Premarket

Approval, Center for Food Safety and Applied

Nutrition.

[FR Doc. 96–17105 Filed 7–3–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 92C–0179]

Microbio Resources, Inc.; Withdrawal

of a Color Additive Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

withdrawal, without prejudice to future

filing, of a color additive petition (CAP

1C0237) proposing that the color

additive regulations be amended to

provide for the safe use of comminuted

Haematococcus pluvialis algae meal as

a color additive in aquaculture feeds.

FOR FURTHER INFORMATION CONTACT:

James C. Wallwork, Center for Food

Safety and Applied Nutrition (HFS–

217), Food and Drug Administration,

200 C St. SW., Washington, DC 20204–

0001, 202–418–3066.

SUPPLEMENTARY INFORMATION: In a notice

published in the Federal Register of

June 18, 1992 (57 FR 27256), FDA

announced that a color additive petition

(CAP 1C0237) had been filed by

Microbio Resources, Inc., 6150 Lusk

Blvd., suite B–105, San Diego, CA

92121. The petition proposed that 21

CFR part 73 of the color additive

regulations be amended to provide for

the safe use of comminuted

Haematococcus pluvialis algae meal as

a color additive in aquaculture feeds.

Microbio Resources, Inc., 18278 Hadden

Hall Ct., San Diego, CA 92128, has now

withdrawn the petition without

prejudice to a future filing (21 CFR

71.6(c)(2)).

Dated: June 20, 1996.

George H. Pauli,

Acting Director, Office of Premarket

Approval, Center for Food Safety and Applied

Nutrition.

[FR Doc. 96–17059 Filed 7–3–96; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committees; Notice of

Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces

forthcoming meetings of public advisory

committees of the Food and Drug

Administration (FDA). This notice also

summarizes the procedures for the

meetings and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the